• CDC
  • Heart Failure
  • Cardiovascular Clinical Consult
  • Adult Immunization
  • Hepatic Disease
  • Rare Disorders
  • Pediatric Immunization
  • Implementing The Topcon Ocular Telehealth Platform
  • Weight Management
  • Monkeypox
  • Guidelines
  • Men's Health
  • Psychiatry
  • Allergy
  • Nutrition
  • Women's Health
  • Cardiology
  • Substance Use
  • Pediatrics
  • Kidney Disease
  • Genetics
  • Complimentary & Alternative Medicine
  • Dermatology
  • Endocrinology
  • Oral Medicine
  • Otorhinolaryngologic Diseases
  • Pain
  • Gastrointestinal Disorders
  • Geriatrics
  • Infection
  • Musculoskeletal Disorders
  • Obesity
  • Rheumatology
  • Technology
  • Cancer
  • Nephrology
  • Anemia
  • Neurology
  • Pulmonology

Game Change in the World of Atrial Fibrillation

Slideshow

The absence of an antidote may soon disappear as a reason to avoid prescribing a novel oral anticoagulant to patients with atrial fibrillation, based on promising phase III trial results.

The very good news in the world of atrial fibrillation is the recent announcement of phase 3 trial results that showed andexanet alfa provided rapid and near complete reversal (≈94%) of the factor Xa inhibitor apixaban. A similiar trial with rivaroxaban is under way as is a trial to gain FDA approval for the direct thrombin inhibitor antidote idarucizumab. Absence of a reliable reversal agent is believed to be an impediment to wider acceptance of the novel oral anticoagulants NOAC). In other AF news, the FDA has just approved edoxaban, the fourth NOAC available in the United States.

Related Videos
Related Content
New Data Suggest Atrial Fibrillation May be More Common in Younger Adults than Previously Thought / Image credit: ©Horacio Selva/AdobeStock

New Data Suggest Atrial Fibrillation May be More Common in Younger Adults than Previously Thought

April 23rd 2024
Article

Patients with AF aged younger than 65 years have substantial comorbidity burden that may impact their future risk of mortality, reported researchers.

Site Logo

Women and Heart Disease: Incidence, Prevalence, Progress, and the Future

April 6th 2013
Podcast

Female CV mortality lags behind male mortality; lifetime risk assessment, not 10-year risk, is a better estimation tool for women

Apixaban and Aspirin Equal in Preventing Stroke Recurrence in Cardiopathy: Daily Dose / image credit: ©New Africa/AdobeStock

Apixaban and Aspirin Equal in Preventing Stroke Recurrence in Cardiopathy: Daily Dose

February 19th 2024
Article

Your daily dose of the clinical news you may have missed.

The Great Beta-Blocker Debate: The Pros and Cons

The Great Beta-Blocker Debate: The Pros and Cons

December 12th 2012
Podcast

Newly diagnosed hypertension in a patient whose blood pressure is 152/94 mm Hg. What agents will you consider for this patient? Beta-blockers? Think again.

Apixaban Reduced Risk of Stroke in Subclinical Afib Relative to Aspirin but with Greater Risk of Bleeding: ARTRESIA Trial / image: Jeff Healy, MD

Apixaban Reduced Risk of Stroke in Subclinical Afib Relative to Aspirin but with Greater Risk of Bleeding: ARTRESIA Trial

February 2nd 2024
Article

In apixaban-treated participants, risk of stroke or systemic embolism was reduced by 37%; the risk of disability or fatal stroke declined by 49%, but with noted bleeding risk.

COPD Exacerbations May Increase Risk of Severe CV Events by More Than 15-Fold: Cohort Study / image credit heart and lungs ©Morphart Creation/shutterstock.com

COPD Exacerbations May Increase Risk of Severe CV Events by More Than 15-Fold: Cohort Study

January 10th 2024
Article

The risk of severe CV events, including leading to death, was greatest in the first week following an exacerbation but remained significantly elevated 1 year later.

© 2024 MJH Life Sciences

All rights reserved.